Rhythm Corp (RYTM) - Long-Term Debt to Capital Coefficient

Rhythm Pharmaceuticals brings together leading geneticists to combat rare metabolic pathologies, leveraging robust R&D and an RSU system. Historical price action reflects this trajectory, where the indicator stands at 0.43. The business possesses exclusive pricing power over unique treatments, while a growing patient base gradually offsets previous development costs for the innovative drug.

This indicator assesses financial leverage by comparing liabilities with maturities exceeding one year against net assets to determine the degree of debt burden. By analyzing the ratio of long-term loans to equity, an investor can see the impact of share issuances or buybacks; for Rhythm Pharmaceuticals (RYTM), low capital expenditure requirements due to the outsourcing of R&D and production minimize the need for large-scale long-term borrowing.